Silver Book Fact

Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.

Ettinger B, Black D, Mitlak B, Knickerbocker R, et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999; 282(7): 637-45. http://jama.ama-assn.org/cgi/content/abstract/282/7/637?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Reduction+of+Vertebral+Fracture+Risk+in+Postmenopausal+Women+with+Osteoporosis+Treated+with+Raloxifene&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial
Publication
JAMA
Publication Date
1999
Authors
Ettinger B, Black D, Mitlak B, Knickerbocker R, et al.
Volume & Issue
Volume 282, Issue 7
Pages
637-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.